TTOO - T2 Biosystems, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.74
-0.26 (-5.20%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.00
Open5.03
Bid0.00 x 1800
Ask0.00 x 800
Day's Range4.50 - 5.04
52 Week Range3.60 - 9.98
Volume920,958
Avg. Volume614,703
Market Cap207.458M
Beta (3Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-1.62
Earnings DateNov 1, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    T2 Biosystems Announces 2018 Third Quarter Financial and Operational Results Release and Conference Call Date

    LEXINGTON, Mass., Oct. 18, 2018 -- T2 Biosystems, Inc. (Nasdaq: TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical.

  • GlobeNewswire17 days ago

    T2 Biosystems Reports Granting of Inducement Awards

    The inducement awards consist of options to purchase 16,500 shares of T2 Biosystems common stock and have a ten-year term. The exercise price of the options is $6.82, which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on October 2, 2018.

  • GlobeNewswire19 days ago

    T2 Biosystems Announces Customer Presentations at October Conferences

    LEXINGTON, Mass., Oct. 03, 2018 -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical.

  • Here's Why T2 Biosystems Rose as Much as 16% Today
    Motley Fool25 days ago

    Here's Why T2 Biosystems Rose as Much as 16% Today

    The diagnostic innovator provided performance data for a product pipeline candidate aimed at diagnosing Lyme disease.

  • GlobeNewswire26 days ago

    New Data Suggests T2 Biosystems’ T2Lyme™ Panel is More Accurate than Other Diagnostics for Identifying Borrelia Infections for Patients Suspected of Having Early Lyme Disease

    T2 Biosystems, Inc. (TTOO), a leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today new data suggesting the T2Lyme Panel™ is more accurate than other diagnostics for identifying Borrelia infections for patients suspected of having early Lyme disease. Run on the fully automated FDA-cleared T2Dx® Instrument, the T2Lyme Panel is designed to detect Lyme disease-causing bacteria in 3 to 5 hours. The data from a 2017 pre-clinical study evaluated 21 patients enrolled with an erythema migrans (EM) rash with suspected early Lyme disease and assessed with multiple Lyme diagnostics.

  • GlobeNewswirelast month

    T2 Biosystems to Participate in Two Upcoming Investor Conferences

    T2 Biosystems, Inc. (TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, president and chief executive officer, is scheduled to participate in two upcoming investor conferences. The first conference is the Janney Healthcare Conference 2018, which is being held September 17-18 in New York City. This conference will allow institutional investors to meet with the Company but does not include a formal webcast presentation.

  • Should T2 Biosystems Inc’s (NASDAQ:TTOO) Recent Earnings Worry You?
    Simply Wall St.last month

    Should T2 Biosystems Inc’s (NASDAQ:TTOO) Recent Earnings Worry You?

    When T2 Biosystems Inc (NASDAQ:TTOO) released its most recent earnings update (30 June 2018), I wanted to understand how these figures stacked up against its past performance. The two benchmarksRead More...

  • GlobeNewswirelast month

    T2 Biosystems Reports Granting of Inducement Awards

    T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, and T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of TTOO earnings conference call or presentation 2-Aug-18 8:30pm GMT

    Q2 2018 T2 Biosystems Inc Earnings Call

  • GlobeNewswire3 months ago

    T2 Biosystems Reports Granting of Inducement Awards

    T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, and T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology.

  • Associated Press3 months ago

    T2 Biosystems: 2Q Earnings Snapshot

    On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 32 cents. The results matched Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire3 months ago

    T2 Biosystems Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    Quarterly Product Revenue Up 71% Year-Over-Year. Launched the Recently FDA Cleared T2Bacteria Panel, the Flagship Product in the T2Direct Diagnostics Portfolio. Reiterates 2018 Financial Guidance, Including ...

  • GlobeNewswire3 months ago

    T2 Biosystems to Participate in Two Upcoming Conferences

    T2 Biosystems, Inc. (TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, president and chief executive officer, is scheduled to participate in two upcoming investor conferences. This conference will allow institutional investors to meet with the Company but does not include a formal presentation. The second conference is the Canaccord Genuity 38th Annual Growth Conference, which is being held August 8-9 in Boston.

  • ACCESSWIRE4 months ago

    Free Stock Performance Review on Thermo Fisher Scientific and Three Additional Medical Research Stocks

    LONDON, UK / ACCESSWIRE / June 29, 2018/ If you want a free Stock Review on TMO sign up now at www.wallstequities.com/registration. Today, WallStEquities.com has selected the following Medical Laboratories and Research stocks for observation: Syneos Health Inc. (NASDAQ: SYNH), T2 Biosystems Inc. (NASDAQ: TTOO), Thermo Fisher Scientific Inc. (NYSE: TMO), and Bruker Corp. (NASDAQ: BRKR).

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of TTOO earnings conference call or presentation 8-May-18 8:30pm GMT

    Q1 2018 T2 Biosystems Inc Earnings Call

  • PR Newswire5 months ago

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

    88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...

  • TheStreet.com5 months ago

    How to Manage Risk in Biotech Stocks

    Karl is an ex-Brooklynite who now splits time between Miami and London. The ascendancy of the Evil Empire (AKA, my beloved NY Yankees) and the fate of his miserable Mets, who look more like a M.A.S.H. unit than a baseball team for the third year in a row. Karl was quite happy with the news as he had taken my advice and loaded up on the shares in the mid-$4s several months ago and now the stock was trading near $10 on the news.

  • Here's Why T2 Biosystems, Inc. Rose Over 16% Today
    Motley Fool5 months ago

    Here's Why T2 Biosystems, Inc. Rose Over 16% Today

    The diagnostic company is rebounding after a stock offering.